ILC Dover

Articles

Meet the soloPURE™ flexible aseptic isolator, a cost-effective closed-barrier
system for sterile manufacturing that provides a closed Grade-A, aseptic
environment for fill finish activities requiring positive and negative pressures.

The Future of Sterile Manufacturing is soloPURE™

With the growth of highly potent
active pharmaceutical ingredients
(HPAPIs) and multiple-use facilities
that must protect against product
cross contamination, the need for
engineering controls to achieve
high containment has become more
critical.



Retrofit Pharmaceutical Equipment for High Containment and Reduced Risk of Cross Contamination

Learn about the benefits of using a DoverPac® Powder Containment System

DoverPac® Powder Containment System

During this podcast we shall be discussing how sterile potent powders are becoming more common in the bio-pharmaceutical industry and the challenges around handling these powders in conventional aseptic containment systems. Review the overarching benefits of compliant. single use isolator systems when handling sterile products and how they mitigate the risk associated with potent product batch manufacture.

Handling Sterile Potent, Powders Inside a Single Use, Disposable Aseptic Isolator with Martyn Ryder

Podcasts

Handling Sterile Potent, Powders Inside a Single Use, Disposable Aseptic Isolator

A drug’s journey from development to manufacturing to patients is paved with roadblocks and potholes; many threats can derail bio/pharmaceutical processes. Potential solutions to such pitfalls have been discussed for years; however, few manufacturers have embraced technology and process advances to proactively ensure drug supply chain continuity.

The COVID-19 pandemic quickly brought supply chain and manufacturing deficiencies to light. The rapid deployment of select science- and technology-based solutions temporarily filled in productivity, communication, and supply chain gaps.

In this Technology Forum, the editors of Pharmaceutical Technology and BioPharm International share insight from process, manufacturing, and supply chain experts on promising and proven methods to ensure drug production continuity for small-molecule and biologic drugs.

Reinventing Small-Molecule Drug Process Development and Manufacturing

The COVID-19 pandemic and nitrosamines contamination emergency exposed vulnerabilities in the small-molecule drug manufacturing and supply chain. Efforts to enhance continuous manufacturing processes, new technologies for process intensification, and investment in drug manufacturing infrastructure are showing promising results. Hear experts discuss current trends, and how technology and process improvements can advance the development, manufacturing, and distribution of generic and innovator small-molecule drug.

Development and Manufacturing Strategies to Meet Biologic Drug Demand

Manufacturing capacity for biologic drugs, as well as fill-finish operations has been strained in the past year by demand for vaccines and therapies to combat COVID-19. Hear expert insight on how the bio/pharma industry is responding to the demand for materials, equipment, and manufacturing.

Understand strategies to for more efficient and effective small-molecule drug manufacturing

Review regulatory implications of the pandemic and strategies to comply with GMPs

Learn how demand for vaccines is impacting biologics drug manufacturing capacity, and ways to avoid roadblocks.

Session 1: Thursday, April 22, 2021, 10am EDT

Session 2: Thursday, April 22, 2021, 11am EDT

Session 3: Thursday, April 22, 2021, 1pm EDT

: Lonza, Emergent, Thermo Fisher Scientific, ILC Dover, Bora Pharmaceuticals, Patheon  

Webcasts

***Session 1: Thursday, April 22, 2021, 10am EDT, Session 2: Thursday, April 22, 2021, 11am EDT, Session 3: Thursday, April 22, 2021, 1pm EDT***  A drug’s journey from development to manufacturing to patients is paved with roadblocks and potholes; many threats can derail bio/pharmaceutical processes. Potential solutions to such pitfalls have been discussed for years; however, few manufacturers have embraced technology and process advances to proactively ensure drug supply chain continuity.  
